Effect of Termination. In the event of termination of this Agreement pursuant to any of the provisions of this Section 11 (but not in the case of expiration in accordance with Section 10), all rights to the Subject Technology and Patent Rights shall revert to BCM. At the date of any termination of this Agreement, LICENSEE shall immediately cease using any of the Subject Technology and Patent Rights and LICENSEE shall immediately destroy the Subject Technology and send to BCM a written affirmation of such destruction signed by an officer of LICENSEE; provided, however, that LICENSEE may sell any Licensed Products actually in the possession of LICENSEE on the date of termination and may complete the production of Licensed Products then in the process of production and sell the same, provided in each case that LICENSEE continues to submit royalty reports to BCM and pays to BCM the Royalties on all such sales in accordance with Paragraph 5.3 with respect thereto and otherwise complying with the terms of this Agreement.

. No termination pursuant to any of Sections 7.1, 7.2, 7.3, 7.4 or 7.5 shall relieve any of the parties (or the Permitted Transferee, if any) for liability for breach of or default under any of their respective obligations or restrictions under any terminated provision of this Agreement, which breach or default arose out of events or circumstances occurring or existing prior to the date of such termination.

Effect of Termination. In case of any termination or expiration of this Agreement, all rights and obligations of the Parties shall cease immediately, unless otherwise indicated in this Section below or elsewhere in this Agreement:

Effect of Termination. The provisions of this Section 6 shall apply to any termination of the Executive’s employment hereunder.

All Terminations Other Than by the Company Without Cause or by the Executive With Good Reason. If the Executive's employment is terminated under any circumstances other than a Qualifying Termination (as defined below) (including a voluntary termination by the Executive without Good Reason pursuant to [Section 6(c)], a termination by the Company for Cause pursuant to [Section 6(b)] or due to the Executive's death or Disability pursuant to [Section 6(a)]), the Company's obligations under this Agreement shall immediately cease and the Executive shall only be entitled to receive # the Base Salary that has accrued and to which the Executive is entitled as of the effective date of such termination and to the extent consistent with general Company policy, accrued but unused paid time off through and including the effective date of such termination, to be paid in accordance with the Company's established payroll procedure and applicable law but no later than the next regularly scheduled pay period, # unreimbursed business expenses for which expenses the Executive has timely submitted appropriate documentation in accordance with Section 5 hereof, and # any amounts or benefits to which the Executive is then entitled under the terms of the benefit plans then-sponsored by the Company in accordance with their terms (and not accelerated to the extent acceleration does not satisfy Section 409A of the Internal Revenue Code of 1986, as amended, (the "Code") (the payments described in this sentence, the "Accrued Obligations").

Effect of Termination. In the event of any termination of this Agreement pursuant to Section 2, Executive’s employment shall terminate, and Executive and Employer shall have the following obligations:

Effect of Termination. Upon termination of the Executive’s employment for any reason during the Employment Period, Executive shall be deemed to have resigned from the Board and any other officer or director positions he holds with the Company.

Upon termination of any Service or Sub-Service in accordance with this Agreement, Service Provider will have no further obligation to provide such terminated Service or Sub-Service and Service Recipient shall have no obligation to pay any Service Fee relating to any such terminated Service or Sub-Service; provided that Service Recipient shall remain obligated to Service Provider for # any Service Fee or other required amounts owed and payable in respect of such terminated Service or Sub-Service that was provided prior [[Organization B:Organization]] effective date of termination and # any other fees or expenses of Service Provider or its Affiliates in connection with terminating and otherwise winding down the terminated Services or Sub-Services, including any fees payable to a Third Party Service Provider or under any third party contract associated with the provision of the terminated Services. In connection with the termination of any Service or Sub-Service, the provisions of this Agreement not relating solely to such terminated Service or Sub-Service shall survive any such termination.

Effect of Termination. Upon expiration or termination of this Agreement, # the licenses granted to each Party to conduct a Combined Therapy Trial in Sections 3.1 and 3.2 shall terminate, and # the Parties shall use reasonable efforts to wind down activities under this Agreement in a medically reasonable manner and avoid incurring any additional expenditures or non-cancellable obligations; provided that, if sufficient quantities of the Nektar Compound and the CPI Compound are available, # in the case of termination pursuant to Section 12.4, BioXcel may continue to dose subjects enrolled in any then ongoing Combined Therapy Trial through completion of the applicable Protocol if dosing is required by the applicable Regulatory Authority(ies) and/or Applicable Law(s); and # in the case of termination by Nektar pursuant to Section 12.5, BioXcel may continue to dose subjects enrolled prior to receipt of the termination notice from Nektar in any then ongoing Combined Therapy Trial through completion of the applicable Protocol. Any such wind-down activities will include the return to Nektar, or destruction, of all Nektar Compound provided to BioXcel and not consumed in the Combined Therapy Trials. If applicable, upon termination of this Agreement, the Parties shall remain responsible pursuant to the terms of this Agreement for any expenses incurred prior to such termination and that are associated with terminating any ongoing clinical trial work and/or result from such ongoing activities under this Agreement solely to the extent such activities are deemed necessary by BioXcel (after discussion at a meeting of the JDC) based on reasonable medical judgment to protect the health of subjects participating in any Combined Therapy Trial.

. Upon termination of the Collaboration Agreement in accordance with Section 2.1 (and without prejudice to Section 2.1), the following consequences shall apply: